Population: Adults (18-64 years)

Nguyen

France
|
2021-2022
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Pinargote-Celorio

Spain
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

Colaneri

Italy
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Caso

Spain
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

Vicente-Valor

Spain
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Pereta

Spain
|
2020-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

PANTHER

United Kingdom
|
2026
  • Adults (18-64 years)
  • General population
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Influenza
  • Avian Influenza
  • Pharmacological intervention
  • Immunomodulator
  • Baricitinib
  • Statins
  • Simvastatin

EU-PROACT

France Norway Spain Belgium Italy United Kingdom Ireland Austria The Netherlands Switzerland
|
2025
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Influenza
  • Avian Influenza

ECRAID-PRIME

Belgium France Germany Ireland Poland Spain United Kingdom Georgia
|
2024
  • Adults (18-64 years)
  • Community
  • Primary care
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Influenza
  • Avian Influenza
  • Pharmacological intervention
  • Nitric Oxide Nasal Spray

ECRAID-REMAP-CAP

Belgium Croatia Czech Republic Estonia France Germany Hungary Ireland Italy The Netherlands Portugal Serbia Slovenia Spain Switzerland United Kingdom
|
2018
  • Adults (18-64 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Influenza
  • Avian Influenza
  • Pharmacological intervention
  • Immunomodulator
  • Corticosteroid
  • Baloxavir
  • Oseltamivir

ECRAID-EU-RECOVERY

France Italy The Netherlands Belgium Estonia Portugal Romania Spain Sweden
|
2020
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Influenza
  • Avian Influenza
  • Pharmacological intervention
  • Antivirals
  • Corticosteroid
  • Baloxavir
  • Oseltamivir

Zeyen

Germany
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox